Actively Recruiting
Evaluation of SUBMO Hydrogel Compared to Normal Saline for Endoscopic Removal of Large Superficial Colorectal Lesions Assessing Safety and Effectiveness
Led by i+Med S.Coop. · Updated on 2026-07-09
300
Participants Needed
4
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating whether SUBMO, a submucosal injection hydrogel made of high-molecular-weight hyaluronic acid and methylene blue, is as effective and safe as normal saline in the endoscopic removal of superficial colorectal lesions larger than 10 mm. The study aims to show that SUBMO is not less effective than saline in achieving complete lesion removal and to carefully monitor any serious adverse events related to the procedure. Additional goals include assessing the volume of product used, procedure duration, ease of removal, and other potential side effects such as bleeding or pain. Participants are randomly assigned to one of two groups one receives SUBMO as the injection agent to create a stable cushion under the lesion, and the other receives normal saline combined with a surface dye for visibility. The procedure involves standard endoscopic mucosal resection or submucosal dissection techniques. SUBMO is supplied in prefilled syringes and is designed to provide longer-lasting support and better visualization during resection. The control group uses saline with added dye, which provides a shorter-lasting mucosal lift and serves as the current standard of care. During the study, participants undergo endoscopic removal of their colorectal lesions with detailed monitoring of procedure success, safety events, and various clinical and lesion-related factors. Researchers collect information on lesion size, location, resection technique, number of fragments, and complications. They also record procedure time, injection volumes, and endoscopists subjective ratings of ease and usability. Safety is closely tracked for serious adverse events and common complications such as bleeding, fever, and pain, with follow-up extending up to one month after the procedure.
CONDITIONS
Brief Title
Clinical Trial to Evaluate the Efficacy and Safety of SUBMO® as a Submucosal Injection Agent in Endoscopic Resection of Superficial Gastrointestinal Lesions.
Research Team
J
Josune Torrecilla
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here